×
Soleno Therapeutics EBITDA 2013-2024 | SLNO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Soleno Therapeutics ebitda from 2013 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Soleno Therapeutics EBITDA 2013-2024 | SLNO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Soleno Therapeutics ebitda from 2013 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$88.7B
Takeda Pharmaceutical (TAK)
$47.3B
Merck (MKGAF)
$23.7B
Astellas Pharma (ALPMY)
$21.5B
Summit Therapeutics (SMMT)
$19B
Sandoz Group AG (SDZNY)
$17.5B
United Therapeutics (UTHR)
$15.4B
Shionogi (SGIOY)
$13.3B
Neurocrine Biosciences (NBIX)
$12.4B
Catalent (CTLT)
$11B
Orion OYJ (ORINY)
$7.4B
Revolution Medicines (RVMD)
$7.3B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.1B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.1B
Crinetics Pharmaceuticals (CRNX)
$4.2B
Corcept Therapeutics (CORT)
$4.1B
Dyne Therapeutics (DYN)
$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
PTC Therapeutics (PTCT)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.5B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Xencor (XNCR)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Harrow (HROW)
$1.5B
Cassava Sciences (SAVA)
$1.5B
Ardelyx (ARDX)
$1.4B